|| List of recent Factor-related patents
| Plant having complex disease resistance|
The present invention relates to plants that have been transformed so as to have both disease resistance and acceptable agronomic traits. More specifically, the present invention relates to transgenic plants that have acquired disease resistance through expression in the plants of a polynucleotide encoding the transcription factor wrky45 in an infection-responsive manner, and methods for generating the transgenic plants..
| Refund purchase system|
A system provides a software program that receives tax return information with an anticipated tax refund and taxpayer demographic information and automatically generates optional sell offers with corresponding discounted purchase prices. The sell offers and purchase prices are calculated for a portion of the refund at different levels (high, medium, low), and the system generates the documents that the taxpayer electronically signs to authenticate the offers.
| System, computer-implemented method, and non-transitory, computer-readable medium to determine relative market value of a sale group of livestock based on genetic merit and other non-genetic factors|
Systems, computer-readable medium having computer program, and related computer implemented methods are provided to determine the relative market value of a sale group and to generate a genetic merit scorecard. Such systems, computer-readable medium having computer program, and related computer implemented methods utilize the genetic merit estimates of relatives of a sale group, along with associated economic weighting factors to determine the relative market value of the sale group.
| Compositions and methods for inhibiting expression of factor v|
The invention relates to a double-stranded ribonucleic acid (dsrna) for inhibiting the expression of factor v, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of factor v. The invention also relates to a pharmaceutical composition comprising the dsrna together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of factor v using the pharmaceutical composition; and methods for inhibiting the expression of factor v in a cell..
| Modulation of growth hormone receptor expression and insulin-like growth factor expression|
Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-i (igf-i). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor.
| Five-membered heterocycles useful as serine protease inhibitors|
Or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables a, l, z, r3, r4, r6, r11, x1, x2, and x3 are as defined herein. The compounds of formula (i) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor xa, factor xia, factor ixa, factor viia and/or plasma kallikrein.
| Methods, kits & antibodies for detecting intact fibroblast growth factor 21|
Disclosed are methods, compositions and kits related to immunoassays for detection of fgf21 using antibodies specific to the n-terminal and/or c-terminal of fgf21. The present invention provides antibodies specific to n-terminal or c-terminal peptide of fgf21.
| Anti c-met antibodies|
The present invention relates to antibodies that specifically bind to the human c-met receptor protein and that act as strict antagonists of hepatocyte growth factor (hgf)-mediated activation of the c-met receptor and also inhibit hgf-independent activation of the human c-met protein.. .
| Compositions derived from stem cell released molecules & methods for formulation thereof|
Compositions for use in treatment of a variety of tissue diseases include stem cells and stem cell released molecules (srm's) suspended in an aqueous solution with a cellulosic material or other thickening agent. The stem cells and srm's can be derived from one or more distinct cell lines.
| Vaccines targeting cellular death receptors|
The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells within the host's body. The therapeutics are vaccine compositions, including genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family.
| Chip package having terminal pads of different form factors|
A chip package includes an integrated circuit chip. A first group of terminal pads of the chip package is electrically connected to the integrated circuit chip and a second group of terminal pads of the chip package is electrically connected to the integrated circuit chip.
| Hydrocarbon delivery apparatus|
An apparatus for controlling hydrocarbon delivery in an exhaust gas processing system of an engine that includes a heat generating device and a dpf, comprising a fuel injector and a control manifold, which has a pressure chamber holding compressed air for separating hydrocarbon from exhaust gas, and is fluidly connected to the fuel injector, a fuel control solenoid valve for controlling hydrocarbon supply, a pressure sensor, and a volume changing device, which provides a linear relationship between its volume change and pressure change in the control manifold. With the volume changing device, a deterioration factor value indicative of performance change of the hydrocarbon delivery device can be calculated for compensating temperature control, calculating the hydrocarbon conversion efficiencies of the heat generating device and the dpf in the exhaust gas processing system, detecting failures and mal-functions in the exhaust gas processing system and the engine..
|Polynucleotides and polypeptides in plants|
The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant. Sequence information related to these polynucleotides and polypeptides can also be used in bioinformatic search methods and is also disclosed..
|Polynucleotides and polypeptides that confer increased yield, size or biomass|
The present description relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant, including the traits of increased yield, size or biomass.. .
A bioreactor for the formation of mature blood cells from haematopoietic stem cells is disclosed. The bioreactor comprises a first zone and a second zone.
|Multiple growth factor compositions, methods of fabrication, and methods of treatment|
Disclosed are compositions with sustained-release carriers associated with at least two different types of growth factors and methods of fabrication and treatments thereof. In some embodiments, simultaneous release of the growth factors may be preferred while in other embodiments, sequential release of the growth factors may be preferred.
|Microbial growth factors|
Disclosed are methods of cultivating or isolating a microorganism using one or more quinones as growth factors. Also disclosed are methods of treating a mammalian species with deficiency in symbionts using such compounds..
|Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses|
The invention relates to inhibitory anti-factor xii/fxiia antibodies and methods of their use.. .
|Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2/kdr)|
Phage displayed recombinant antibody library was developed and the library was screened against vegfr-2. After screening and elisa experiments two recombinant antibodies showing binding properties to vegfr-2 was obtained.
|Plant transcriptional regulators|
The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having improved tolerance to drought, shade, and low nitrogen conditions, as compared to wild-type or reference plants.. .
|Transgenic plants with enhanced agronomic traits|
This invention provides recombinant dna for expression of proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants. Also provided by this invention is transgenic seed for growing a transgenic plant having recombinant dna in its genome and exhibiting an enhance agronomic trait, i.e.
|Optimized consistent request distribution for balanced load distribution in a content delivery network|
Some embodiments provide a proprietary 64-bit consistent distribution scheme that preserves the efficiencies of carp while providing a significantly more balanced distribution of requests that is on par with schemes reliant on computationally expensive cryptographic hashes. The scheme performs hashing of requested urls and identifiers of available servers over a 64-bit space while optimizing the hashing to remove computationally expensive operations.
|Chronic population based cost model to compare effectiveness of preventive care programs|
Our invention is a cost model for healthcare, based not on “age”, as it is done currently, but on “chronic illness” as a risk factor. Using the model it is possible to derive two burden numbers, “primary” and “secondary” that is an inverse measure of the success of primary and secondary preventive care programs.
|Topography simulation apparatus, topography simulation method and recording medium|
In one embodiment, a topography simulation apparatus includes a division module to divide a substance surface into plural computing elements, a determination module to extend straight lines in plural directions from each computing element, and to determine whether each straight line contacts the substance surface and determine which computing element each straight line contacts, and a calculation module to calculate, based on results of the determinations, a direct flux of a reactive species directly reaching each computing element, and a form factor indicating a positional relationship between the computing elements. When the determinations are performed to calculate the form factor in a case where an ionic species reaching each computing element is reflected, the determinations are performed by setting a cut-off angle for a reflection direction of the ionic species, and limiting the directions in which the straight lines are extended within a range of the cut-off angle..
|Use of anti-factor xi antibodies for prevention of thrombus formation|
The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor xi and that inhibit factor xi activation and/or activity. The factor xi-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor xi activation and/or wherein inhibition of factor xi has a beneficial effect..
|Compositions and methods for treatment of metabolic disorders and diseases|
The invention relates to variants and fusions of fibroblast growth factor 19 (fgf19), variants and fusions of fibroblast growth factor 21 (fgf21), fusions of fibroblast growth factor 19 (fgf19) and/or fibroblast growth factor 21 (fgf21), and variants or fusions of fibroblast growth factor 19 (fgf19) and/or fibroblast growth factor 21 (fgf21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.. .
|Monoclonal antibodies to fibroblast growth factor receptor 2|
The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.. .
|Modified factor viii and factor ix genes and vectors for gene therapy|
The present invention relates to a modified and optimized factor viii or factor ix nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia..
|Novel apoc-i isoforms and their use as biomarkers and risk factors of atherosclerotic disease|
Novel isoforms of apolipoprotein c-i (apoc-i), namely apolipoprotein c-i1 (apoc-i1) and apolipoprotein c-i1′ (apoc-i1′), both of which have a molecular weight of approximately 90 daltons greater than native apolipoprotein c-i (seq id no:6) and native apolipoprotein c-i′ (seq id no:7), are shown to be both biomarkers for diagnosing atherosclerotic disease as well as risk factors for subjects having increased risk of developing an atherosclerotic disease.. .
|Method of administering porcine b-domainless fviii|
The present invention provides a method of administering porcine b-domainless factor viii (obi-1) to a patient having factor viii deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant b-domainless porcine fviii, termed obi-1, has greater bioavailability compared to the natural porcine fviii partially purified from porcine plasma, termed hyate:c.
Multimeric fusion proteins of an ig-like domain of flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization.
|Anti-pdgfr-beta antibodies and uses thereof|
The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity.
|Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof|
Acridine containing cisplatin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective cisplatin compounds to the nucleus in cancer cells is disclosed using one or more amino acids, one or more sugars, one or more polymeric ethers, c1-6alkylene-phenyl-nh—c(o)—r15, folic acid, αvβ3 integrin rgd binding peptide, tamoxifen, endoxifen, epidermal growth factor receptor, antibody conjugates, kinase inhibitors, diazoles, triazoles, oxazoles, erlotinib, and/or mixtures thereof; wherein r15 is a peptide..
|Method and a device for defining a look-up system for a network element of a software-defined network|
A method for defining a look-up system having functionality suitable for a network element of a software-defined network “sdn” includes maintaining (401) data specifying a set of look-up tables so that the look-up system is capable of being constructed in alternative ways using one or more look-up tables of the set of look-up tables and each of the look-up tables has a look-up table specific resource consumption estimate indicating a load factor of at least one component of the network element when running operations related to the look-up table. The method includes selecting (402), on the basis of the look-up table specific resource consumption estimates, such one of the alternative ways of constructing the look-up system which provides a look-up system that is optimal, or at least suitable, for the network element..
|Method and a controller system for configuring a software-defined network|
A method for configuring a network element of a software-defined network “sdn” includes retrieving (401), for different look-up tables, a look-up table specific resource consumption estimate indicating a load factor of at least one component of the network element when running operations related to the look-up table, determining (402), on the basis of the look-up table specific resource consumption estimates, a resource consumption estimate for at least one look-up system including one or more of the look-up tables and having functionality suitable for the network element, and sending (404) to the network element, if the network element is capable (403) of running the look-up system, configuration data defining the look-up system. The method provides a possibility to avoid configuring network elements to overload and, on the other hand, the resource consumption estimates related to different network elements can be used for optimizing the software-defined network as a whole..
|Augmented i/o for limited form factor user-interfaces|
The claimed subject matter relates to an architecture that can enhance and/or simplify tactile-based i/o transactions in connection with a user-interface (ui) of limited form factor. In particular, the architecture can monitor a position of a selector object such as an operator's finger relative to a ui display as the selector object hovers or moves above the ui display.
|Outlier detection for analyte sensors|
Systems and methods for processing sensor data and end of life detection are provided. In some embodiments, a method for determining the end of life of a continuous analyte sensor includes evaluating a plurality of risk factors using an end of life function to determine an end of life status of the sensor and providing an output related to the end of life status of the sensor.
|Drug delivery using a sacrificial host|
Implantable drug-doped component, e.g., a cochlear implant, including host material, a host-embedded drug, a sacrificial material integrated with the host. Sacrificial material facilitates release of drug from the component.
|Small form factor medical sensor structure and method therefor|
A measurement system for measuring a parameter of the muscular-skeletal system is disclosed. The measurement system comprises a capacitor, a signal generator, a digital counter, counter register, a digital clock, a digital timer, and a data register.
|Small molecule antagonists of phosphatidylinositol-3,4,5-triphosphate (pip3) and uses thereof|
Disclosed are new members of a class of non-lipid small molecule inhibitors which interfere with the interaction between phosphoinositol-3,4,5-triphosphate (pip3) and pleckstrin homology (ph) domains. These molecules target a broad range of pip3-dependent signaling events in vitro and exert significant anti-tumor activity in vivo, with improved activity and selectivity toward particular ph domains.
|Connective tissue growth factor antisense oligonucleotides|
The present invention relates to antisense oligonucleotides that target human ctgf mrna and inhibit ctgf mrna expression. Additionally, regions of human ctgf mrna that are exceptionally sensitive to antisense inhibition are disclosed.
|Combination therapy in treatment of oncological and fibrotic diseases|
The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (vegfrs) in conjunction with a thrombin inhibitor.. .
|Inhibitors of the fibroblast growth factor receptor|
Described herein are inhibitors of fgfr, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.. .
|Activation and expansion of t-cells using an engineered multivalent signaling platform as a research tool|
Provided are a system and methods for selectively inducing expansion of a population of t cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of ctls, preferably human ctls.
|Method for identifying a malodor inhibitor|
Provided is a method for identifying a malodor inhibitor based on a response of an olfactory receptor. The present invention provides a method for identifying a malodor inhibitor including: adding a test substance and a malodor-causing substance to at least one olfactory receptor selected from the group consisting of or5p3, or5k1, or2w1, or8h1, and a polypeptide which has 80% or more identity in amino acid sequence to any one of the aforementioned polypeptides; measuring the response of the olfactory receptor to the malodor-causing substance; identifying the test substance which can suppress the response of the olfactory receptor based on the measured response; and selecting, as a malodor inhibitor, the test substance which can suppress the response of the olfactory receptor..
|Soluble tumor necrosis factor receptor (stnf-r) used as a targeting agent to treat arthritis and other diseases|
This invention describes the use of stnf-r as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the stnf-r coated liposomes.
|Anti-tumor necrosis factor alpha (tnf-a) antibody used as a targeting agent to treat arthritis and other diseases|
This invention describes the use of anti-tnf-a antibody as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the anti-tnf-a coated liposomes.
|Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides|
The present invention provides immunogenic peptides comprising the amino acid sequence of seq id no: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic t cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines..
|Methods of administering anti-tnfalpha antibodies|
Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
|Coagulation factor ix compositions and methods of making and using same|
The present invention relates to compositions comprising factor ix coagulation factors linked to extended recombinant polypeptide (xten), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.. .
|Factor viia-polysialic acid conjugates having prolonged in vivo half-life|
The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor viia (fviia) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a fviia molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of fviia, fviii, or fix.